Combined liver-kidney transplant aims to restore normal hepatic metabolic function and renal fluid filtration in patients suffering from dual-organ failure. The mechanism involves surgical replacement of diseased organs with vascularized donor grafts, usually from a deceased donor. Guidelines from the Organ Procurement and Transplantation Network (OPTN 2023) and the American Association for the Study of Liver Diseases (AASLD 2021) govern allocation and surgical sequencing for this complex intervention.

The combined liver-kidney transplant is performed under general anesthesia. First, the total native hepatectomy (surgical removal of the diseased liver) is performed via a subcostal or Mercedes-Benz abdominal incision. The donor liver graft is implanted using either total inferior vena cava replacement or the piggyback technique, followed by vascular anastomoses (hepatic vein, portal vein, hepatic artery) and biliary reconstruction (choledochocholedochostomy or Roux-en-Y choledochojejunostomy). After restoring liver reperfusion and ensuring vascular stability, the kidney transplant proceeds, positioned extraperitoneally in the iliac fossa with renal vessel anastomoses to the external iliac artery and vein, completed by ureteroneocystostomy over a protective ureteral stent.

Evidence demonstrates that combined liver-kidney transplant provides significant survival advantages for patients with combined end-stage liver disease and severe renal failure compared to solitary organ transplantation or supportive medical therapy (AASLD/AST guidelines 2021). The donor liver graft confers an immunoprotective effect on the co-transplanted kidney graft, markedly decreasing the incidence of hyperacute and acute cellular rejection through donor antigen clearance and soluble human leukocyte antigen absorption.

Inpatient post-operative recovery typically lasts 14 to 21 days, beginning in the intensive care unit for invasive hemodynamic monitoring and early graft assessment. Surgical drain removal, physical mobilization, and oral immunosuppression titration occur over the first two weeks. Outpatient recovery spans 3 to 6 months, requiring frequent laboratory draws, therapeutic drug monitoring, routine renal biopsies, and protocol infectious disease prophylaxis.

Combined liver-kidney transplant treats comorbid severe liver failure and permanent renal impairment. Primary conditions include end-stage liver disease (cirrhosis from metabolic dysfunction-associated steatohepatitis, hepatitis B or C, alcohol-related liver failure) accompanied by chronic kidney disease stage 5, sustained acute kidney injury requiring hemodialysis, or inherited metabolic conditions like primary hyperoxaluria type 1 and polycystic liver and kidney disease.

Preparation involves an extensive pre-transplant workup: cardiopulmonary testing (echocardiogram, coronary angiography if indicated), tissue renal biopsy when intrinsic kidney disease versus functional hepatorenal syndrome is uncertain, crossmatching, infection screening, vascular CT angiography, nutritional optimization, and formal evaluation by hepatology, nephrology, transplant surgery, infectious disease, and social work.

Complications are categorized by timeline and severity. Immediate risks include primary graft non-function, vascular thrombosis (hepatic artery thrombosis, portal vein thrombosis, renal vessel thrombosis), surgical hemorrhage, biliary leaks, and urine leaks. Intermediate risks include acute cellular rejection, antibody-mediated rejection, opportunistic infections (cytomegalovirus, fungal infections), and calcineurin inhibitor nephrotoxicity. Long-term risks include chronic allograft nephropathy, post-transplant lymphoproliferative disorder, post-transplant diabetes mellitus, and cardiovascular disease.

The clinical journey begins with an extensive dual-organ evaluation by a multidisciplinary transplant panel. Once listed under standardized national allocation criteria, the candidate waits for organ matching. When compatible donor organs are accepted, the multi-stage transplantation is executed, followed by intensive care monitoring, protocol immunosuppressive therapy, short-term inpatient rehabilitation, and lifelong outpatient surveillance.